08:26 AM EDT, 08/21/2024 (MT Newswires) -- Aditxt, Inc. , a health innovation platform, entered Wednesday into a third amending agreement with Appili Therapeutics, Inc. ( APLIF ) , a biopharmaceutical company.

Under the terms of the arrangement agreement announced on April 2, 2024, Aditxt, through its wholly-owned subsidiary Adivir, Inc., agreed to acquire all outstanding Class A common shares of Appili. Under a third amending agreement, noted Wednesday, the agreement was amended to change the outside date from September 30, 2024 to November 19, 2024; and require Appili to convene an annual and special shareholder's meeting; and change the deadline to convene a special shareholders' meeting to consider the deal from September 30, 2024 to November 6, 2024; and change the deadline for Aditxt to complete the financing from September 15, 2024 to October 18, 2024; and have completion of the continuance as a condition to completion of the arrangement.

Wednesday's statement noted the transaction is conditional upon Aditxt raising at least US$20 million in financing before closing. In addition, completion of the transaction is subject to other customary conditions, including the receipt of all necessary court, regulatory, and stock exchange approvals. No assurance can be given that all of the conditions to closing will be obtained or satisfied or that the transaction will ultimately close.